A Multicenter, Open Label, Long-Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 07 May 2012 Planned number of patients changed from 216 to 245 as reported by ClinicalTrials.gov.
- 22 Mar 2012 Actual patient number 314 added as reported by ClinicalTrials.gov.